Mouse Monoclonal Anti-Collagen I antibody (STJ98915)

$99.00$319.00

Reactivity: Human, Mouse, Rat
Applications: WB, IHC, IF, ELISA
Conjugation: Unconjugated
Supplier: St John’s Laboratory Ltd.

Clear
-$50 as credit for submitting review for primary antibody
Shipping notice:
Product will be delivered in 6 to 8 Business Days

Antibody Validation Project, Antibody Trial Sample, Antibody Free Sample for your own antibody validation and submitting antibody reviews, AntibodyPlus

Mouse Monoclonal Anti-Collagen I antibody (STJ98915)

Supplier: St John’s Laboratory Ltd.

Recommended applications: WB, ELISA

Recommended dilution: WB 1:500-2000; ELISA 1:10000-20000

Recommended protocols: check protocols

Image descriptions:

Click or hover above images to see image description for Anti-Collagen I antibody (STJ98915).

Alternative names:

Check alternative names for the antibody

Expand

|COL1A1 antibody|Alpha 1 type I collagen antibody|Alpha-1 type I collagen antibody|CO1A1_HUMAN antibody|COL1A1 antibody|Collagen alpha-1(I) chain antibody|Collagen type I alpha 1 antibody|Procollagen type I C terminal propeptide antibody|Anti-PICP antibody [8] (ab17202)
SCBT cat No: sc-59772|sc-293182|sc-8784|sc-25974|sc-28657|sc-8783|sc-8786|sc-393573|sc-166865|

Name

Anti-Collagen I antibody

Catalogue No.

STJ98915

Reactivity

Human, Mouse, Rat

Specificity

Anti-Collagen I antibody detects endogenous Collagen I protein.

Immunogen

Synthetic Peptide of Collagen I.

Host

Mouse

Applications

WB, ELISA

Recommended dilution

WB 1:500-2000; ELISA 1:10000-20000

Clonality

Monoclonal

Conjugation

Unconjugated

Molecular weight

139kDa

Formulation

Anti-Collagen I antibody was tube-contained in liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration

1 mg/ml

Purification

Anti-Collagen I antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Storage

-20 Celsius degree. Avoid repeated freeze/thaw cycles.

Alternative antibody names

COL1A1 antibody, Alpha 1 type I collagen antibody, Alpha-1 type I collagen antibody, CO1A1_HUMAN antibody, COL1A1 antibody, Collagen alpha-1(I) chain antibody, Collagen type I alpha 1 antibody, Procollagen type I C terminal propeptide antibody

Database links

UniProt/Swiss-Prot:P02452

Protein function

Type I collagen is a member of group I collagen (fibrillar forming collagen).

Protein tissue specificity

Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite.

Involvement in disease

Caffey disease (CAFFD) [MIM:114000]: Characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Ehlers-Danlos syndrome, classic type (EDS) [MIM:130000]: A connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Ehlers-Danlos syndrome 7A (EDS7A) [MIM:130060]: A connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. Marked by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations. Note=The disease is caused by mutations affecting the gene represented in this entry.; Osteogenesis imperfecta 1 (OI1) [MIM:166200]: An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI1 is a non-deforming form with normal height or mild short stature, and no dentinogenesis imperfecta. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Osteogenesis imperfecta 2 (OI2) [MIM:166210]: An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI2 is characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Osteogenesis imperfecta 3 (OI3) [MIM:259420]: An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI3 is characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera and dentinogenesis imperfecta. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Osteogenesis imperfecta 4 (OI4) [MIM:166220]: An autosomal dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI4 is characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Osteoporosis (OSTEOP) [MIM:166710]: A systemic skeletal disorder characterized by decreased bone mass and deterioration of bone microarchitecture without alteration in the composition of bone. The result is fragile bones and an increased risk of fractures, even after minimal trauma. Osteoporosis is a chronic condition of multifactorial etiology and is usually clinically silent until a fracture occurs. . Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; Note=A chromosomal aberration involving COL1A1 is found in dermatofibrosarcoma protuberans. Translocation t(17;22)(q22;q13) with PDGF.

Protein sequence and domain

Belongs to the fibrillar collagen family. ; Contains 1 fibrillar collagen NC1 domain. ; Contains 1 VWFC domain. The C-terminal propeptide, also known as COLFI domain, have crucial roles in tissue growth and repair by controlling both the intracellular assembly of procollagen molecules and the extracellular assembly of collagen fibrils. It binds a calcium ion which is essential for its function (By similarity).

Protein post-translational modifications

Proline residues at the third position of the tripeptide repeating unit (G-X-P) are hydroxylated in some or all of the chains. Proline residues at the second position of the tripeptide repeating unit (G-P-X) are hydroxylated in some of the chains. .; O-linked glycan consists of a Glc-Gal disaccharide bound to the oxygen atom of a post-translationally added hydroxyl group. .

Protein cellular localization

Secreted, extracellular space, extracellular matrix .

Note

AntibodyPlus can customize Anti-Collagen I antibody according to your requirement, including bulk product size,etc. Please contact info@antibodyplus.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.

Supplier

St John’s Laboratory Ltd.

Product type

Primary antibody

Reviews


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review

There are no reviews for this product yet.
By submitting a review, get following benefits:

1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!

view database submit reviews
 

Immunofluorescence analysis of Mouse brain tissue

1: Collagen I Mouse Monoclonal Antibody(4H10)(red) was diluted at 1:200 (4 degree Celsius,overnight).
2: Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).
3: Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B.
 

Immunofluorescence analysis of Mouse brain tissue

1: Collagen I Mouse Monoclonal Antibody(4H10)(red) was diluted at 1:200 (4 degree Celsius,overnight).
2: Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).
3: Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B.
 

Immunohistochemical analysis of paraffin embedded Human lung cancer tissue

1: Collagen I Mouse Monoclonal Antibody(4H10) was diluted at 1:200 (4 degree Celsius,overnight).
2: Sodium citrate pH 6.0 was used for antibody retrieval (>98 degree Celsius,20min).
3: Secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.
 

Immunohistochemical analysis of paraffin embedded Human stomach cancer tissue

1: Collagen I Mouse Monoclonal Antibody(4H10) was diluted at 1:200 (4 degree Celsius,overnight).
2: Sodium citrate pH 6.0 was used for antibody retrieval (>98 degree Celsius,20min).
3: Secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.
 

Immunohistochemical analysis of paraffin embedded Rat kidney tissue

1: Collagen I Mouse Monoclonal Antibody(4H10) was diluted at 1:200 (4 degree Celsius,overnight).
2: Sodium citrate pH 6.0 was used for antibody retrieval (>98 degree Celsius,20min).
3: Secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.
 

Immunohistochemical analysis of paraffin embedded Rat spleen tissue

1: Collagen I Mouse Monoclonal Antibody(4H10) was diluted at 1:200 (4 degree Celsius,overnight).
2: Sodium citrate pH 6.0 was used for antibody retrieval (>98 degree Celsius,20min).
3: Secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.
 

Immunohistochemical analysis of paraffin embedded Mouse kidney tissue
1: Collagen I Mouse Monoclonal Antibody(4H10) was diluted at 1:200 (4 degree Celsius

1: Collagen I Mouse Monoclonal Antibody(4H10) was diluted at 1:200 (4 degree Celsius,overnight).
2: Sodium citrate pH 6.0 was used for antibody retrieval (>98 degree Celsius,20min).
3: Secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.


Welcome to AntibodyPlus!